(Q37845958)

24 August 2017

title

Development status and future prospects for a vaccine against Chlamydia trachomatis infection (English)

1 reference

24 August 2017

main subject

Chlamydia trachomatis

0 references

1 reference

3

1 reference

24 August 2017

Louise M Hafner

1

1 reference

24 August 2017

David P Wilson

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 August 2013

1 reference

24 August 2017

1 reference

24 August 2017

volume

32

1 reference

24 August 2017

issue

14

1 reference

24 August 2017

page(s)

1563-1571

1 reference

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Risk of sequelae after Chlamydia trachomatis genital infection in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to Chlamydia trachomatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Diagnosis and management of epididymitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Asymptomatic Chlamydia trachomatis infections among sexually active men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia trachomatis infections: progress and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Does population screening for Chlamydia trachomatis raise anxiety among those tested? Findings from a population based chlamydia screening study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Efficacy of interventions to increase the uptake of chlamydia screening in primary care: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Self-reported Chlamydia testing rates of sexually active women aged 15-25 years in the United States, 2006-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Coverage is the key for effective screening of Chlamydia trachomatis in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Developing a realistic sexual network model of chlamydia transmission in Britain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Modelling the effectiveness of chlamydia screening in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia trachomatis incidence and re-infection among young women--behavioural and microbiological characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Transient detection of Chlamydial-specific Th1 memory cells in the peripheral circulation of women with history of Chlamydia trachomatis genital tract infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Understanding human papillomavirus vaccine uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Factors associated with HPV vaccine uptake in teenage girls: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The chlamydial developmental cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydial classification, development and structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Exit strategies of intracellular pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia persistence -- a tool to dissect chlamydia--host interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydial infection of immune cells: altered function and implications for disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Mucosal and systemic immune responses to plasmid protein pgp3 in patients with genital and ocular Chlamydia trachomatis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydial intracellular survival strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The role of IFN-gamma in the outcome of chlamydial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Cleavage of p65/RelA of the NF-kappaB pathway by Chlamydia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Variants in toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydial IFN-gamma immune evasion is linked to host infection tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The cellular paradigm of chlamydial pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Nonhuman primate models used to study pelvic inflammatory disease caused by Chlamydia trachomatis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The effects of a single cervical inoculation of Chlamydia trachomatis on the female reproductive tract of the baboon (Papio anubis)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Towards a safe and effective chlamydial vaccine: lessons from the eye

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A comparison of the effects of a chlamydial vaccine administered during or after a C. muridarum urogenital infection of female mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Development of a Chlamydia trachomatis T cell Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Imperfect vaccines and herd immunity to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Mathematical model of HPV provides insight into impacts of risk factors and vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Modeling the impact of RV144-like vaccines on HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Unraveling the basic biology and clinical significance of the chlamydial plasmid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Induction of immune memory by a multisubunit chlamydial vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Antigenic profiling of a Chlamydia trachomatis gene-expression library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Identification of Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an expression library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Characterization of the humoral immune response to Chlamydia outer membrane protein 2 in chlamydial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

Australian general practitioner chlamydia testing rates among young people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

7 January 2021

inferred from DOI database lookup

Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

7 January 2021

inferred from DOI database lookup

Humoral immune response to plasmid protein pgp3 in patients with Chlamydia trachomatis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.020

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2013.08.020

1 reference

release_fuup7vjypjbmfcg6brzcn76nte

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fuup7vjypjbmfcg6brzcn76nte

24 November 2022

mapped directly with Wikidata item

1 reference